Sign In
Buy PSNL
$10.78
-0.360 (-3.23%)
At Close: Jun 03, 2026
Personalis to Participate at Upcoming Investor Conferences
04:01pm, Thursday, 22'nd Aug 2024
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will participate at the following inve
Personalis: Resetting My Strategy Following The Q2 Beat
07:47am, Sunday, 18'th Aug 2024
PSNL stock has surged from $1.61 to over $4.00 per share following strong Q2 earnings and increased demand for NeXT Personal MRD test. Personalis reported $22.6M in revenue for Q2, with improved gross
Personalis, Inc. (PSNL) Hit a 52 Week High, Can the Run Continue?
10:16am, Tuesday, 13'th Aug 2024
Personalis (PSNL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Personalis, Inc. (PSNL) Q2 2024 Earnings Call Transcript
11:09pm, Wednesday, 07'th Aug 2024
Personalis, Inc. (NASDAQ:PSNL ) Q2 2024 Earnings Conference Call August 7, 2024 5:00 PM ET Company Participants Caroline Corner - IR Chris Hall - CEO and President Aaron Tachibana - CFO and COO Rich C
Personalis (PSNL) Reports Q2 Loss, Tops Revenue Estimates
06:30pm, Wednesday, 07'th Aug 2024
Personalis (PSNL) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.50 per share a year ago.
Myriad Genetics and Personalis Cross-License Foundational MRD Intellectual Property to Broaden Patient Access to Testing
09:00am, Thursday, 11'th Jul 2024
SALT LAKE CITY and FREMONT, Calif., July 11, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq: MYGN), a leader in genetic testing and precision medicine, and Personalis, Inc. (Nasdaq: PSNL) toda
Personalis to Participate at the TD Cowen 3rd Annual Tools / Dx Revolution Conference
04:01pm, Tuesday, 18'th Jun 2024
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that Chris Hall, CEO and President, will join a panel and speak at the TD C
Personalis Provides Dial-in and Updated Date for ASCO Highlights Conference Call
08:00am, Thursday, 13'th Jun 2024
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that it has updated the ASCO data highlights conference call to Friday, Jun
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL) announced today that data presented at the American Society for Clinical Oncology (ASCO) oral podium talks in Chicago, IL demonstrated
Personalis Announces Start of Cancer MRD Testing Commercialization Collaboration with Tempus
09:05am, Friday, 31'st May 2024
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today the commencement of commercialization efforts by Tempus for NeX
Personalis Announces Podium Presentations and Abstracts Accepted at ASCO 2024
09:05am, Wednesday, 22'nd May 2024
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that two podium presentations and multiple posters featuring da
Antares Bolsters Private Wealth Team with Three New Senior Appointments
09:00am, Wednesday, 22'nd May 2024
CHICAGO--(BUSINESS WIRE)--Antares Capital (“Antares”), a leading alternative asset manager with more than $69B in capital under management and administration, today announced three new senior hire
Q2 2024 Earnings Estimate for The Progressive Co. Issued By William Blair (NYSE:PGR)
01:06am, Monday, 20'th May 2024
The Progressive Co. (NYSE:PGR – Free Report) – Equities researchers at William Blair increased their Q2 2024 earnings estimates for Progressive in a research report issued to clients and i
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Friday, 17'th May 2024
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that the Compensation Committee of its Board of Directors grant
Personalis, Inc. (PSNL) Q1 2024 Earnings Call Transcript
11:53pm, Wednesday, 08'th May 2024
Personalis, Inc. (NASDAQ:PSNL ) Q1 2024 Earnings Conference Call May 8, 2024 5:00 PM ET Company Participants Chris Hall - Chief Executive Officer and President Aaron Tachibana - Chief Financial and Ch
